Intellia Therapeutics Announces Presentations at the 24th American Society of Gene and Cell Therapy Annual Meeting
Updated preclinical data will be presented on CRISPR/Cas9-mediated targeted gene insertion to treat alpha-1 antitrypsin deficiency (AATD)
“The data accepted for presentation at ASGCT reflects our ongoing commitment to finding new ways to treat and potentially cure a variety of diseases. Utilizing our modular in vivo insertion technology, we demonstrate the potential to durably restore normal AAT protein levels after a single dose. We continue to advance multiple genome editing strategies for patients living with AATD,” said President and Chief Executive Officer
ASGCT Annual Meeting Presentations & Invited Sessions
Title: “CRISPR/Cas9-Mediated Targeted Gene Insertion Platform Achieves Durable,
Abstract number: 15
Session Title: Delivery Technologies and CRISPR for Therapeutics
Date and Time:
Title: “Characterization of Potential Unintended Genome Editing with CRISPR/Cas9 for New Therapeutics”
Session Type: Pre-Meeting Program
Session Title: Moving Genome Editing to the Clinic: from Technology to Therapeutics
Date and Time:
Presenting Author: Daniel O’Connell Ph.D., director of Intellia’s platform development group
Title: “Development of Systemic CRISPR-Based Therapeutics”
Session Title: Genome Editing – Clinical and Preclinical Updates
Date and Time:
Additional data collected will be included in final meeting presentations. All abstracts for the ASGCT Annual Meeting are available on ASGCT’s website here.
Intellia Therapeutics is a leading clinical-stage genome editing company, focused on the development of proprietary, potentially curative therapeutics using the CRISPR/Cas9 system. Intellia believes the CRISPR/Cas9 technology has the potential to transform medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single administration, and creating enhanced engineered cells that can treat oncological and immunological diseases. Intellia’s combination of deep scientific, technical and clinical development experience, along with its leading intellectual property portfolio, puts it in a unique position to unlock broad therapeutic applications of the CRISPR/Cas9 technology and create new classes of therapeutic products. Learn more about Intellia and CRISPR/Cas9 at intelliatx.com. Follow us on Twitter @intelliatweets.
This press release contains “forward-looking statements” of
Any forward-looking statements in this press release are based on management’s current expectations and beliefs of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: risks related to Intellia’s ability to protect and maintain its intellectual property position; risks related to Intellia’s relationship with third parties, including its licensors and licensees; risks related to the ability of its licensors to protect and maintain their intellectual property position; uncertainties related to the authorization, initiation and conduct of studies and other development requirements for its product candidates; the risk that any one or more of Intellia’s product candidates will not be successfully developed and commercialized; and the risk that the results of preclinical studies or clinical studies will not be predictive of future results in connection with future studies. For a discussion of these and other risks and uncertainties, and other important factors, any of which could cause Intellia’s actual results to differ from those contained in the forward-looking statements, see the section entitled “Risk Factors” in Intellia’s most recent annual report on Form 10-K as well as discussions of potential risks, uncertainties, and other important factors in Intellia’s other filings with the
Interim Head of
Source: Intellia Therapeutics, Inc.